{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:33:59Z","timestamp":1788654839683,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Janssen Scientific Affairs, LLC, a Johnson & Johnson Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02942-6","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T09:02:16Z","timestamp":1723626136000},"page":"3868-3887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Treatment Persistence Among Advanced Therapy-Na\u00efve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab"],"prefix":"10.1007","volume":"41","author":[{"given":"Maryia","family":"Zhdanava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Korsiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"2942_CR1","doi-asserted-by":"publisher","first-page":"175628482211381","DOI":"10.1177\/17562848221138160","volume":"15","author":"N Aslam","year":"2022","unstructured":"Aslam N, Lo SW, Sikafi R, et al. A review of the therapeutic management of ulcerative colitis. Therap Adv Gastroenterol. 2022;15:17562848221138160. https:\/\/doi.org\/10.1177\/17562848221138160.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2942_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ibd\/izz182","volume":"26","author":"Y Ye","year":"2020","unstructured":"Ye Y, Manne S, Treem WR, et al. Prevalence of inflammatory bowel disease in pediatric and adult populations: recent estimates from large national databases in the United States, 2007\u20132016. Inflamm Bowel Dis. 2020;26(4):619\u201325. https:\/\/doi.org\/10.1093\/ibd\/izz182.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2942_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"key":"2942_CR4","unstructured":"AbbVie Inc. RINVOQ\u00ae (upadacitinib) Highlights of Prescribing Information 2023. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 9 Feb 2024."},{"key":"2942_CR5","unstructured":"Bristol Myers Squibb Company. ZEPOSIA\u00ae (ozanimod) Highlights of Prescribing Information 2023. https:\/\/packageinserts.bms.com\/pi\/pi_zeposia.pdf. Accessed 9 Feb 2024."},{"issue":"5","key":"2942_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006.","journal-title":"Gastroenterology"},{"key":"2942_CR7","unstructured":"Abbott. Abbott's Humira\u00ae (adalimumab) receives U.S. FDA approval for the treatment of adult patients with moderate to severe ulcerative colitis 2012. https:\/\/abbott.mediaroom.com\/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis#:~:text=Abbott's%20HUMIRA%C2%AE%20(adalimumab)%20Receives,Ulcerative%20Colitis%20%2D%20Sep%2028%2C%202012. Accessed 9 Feb 2024."},{"issue":"13","key":"2942_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"2942_CR9","unstructured":"US Food and Drug Administration. BLA 761044\/S-003 BLA 125261\/S-152 Supplement Approval 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/761044Orig1s003,%20125261Orig1s152ltr.pdf. Accessed 12 Feb 2024."},{"issue":"6","key":"2942_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780\u20137. https:\/\/doi.org\/10.1136\/gut.2010.221127.","journal-title":"Gut"},{"issue":"2","key":"2942_CR11","doi-asserted-by":"publisher","first-page":"257 e1","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257 e1-265. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.032.","journal-title":"Gastroenterology"},{"issue":"1","key":"2942_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227914","volume":"15","author":"A Armuzzi","year":"2020","unstructured":"Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS ONE. 2020;15(1): e0227914. https:\/\/doi.org\/10.1371\/journal.pone.0227914.","journal-title":"PLoS ONE"},{"issue":"7","key":"2942_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/03007995.2022.2071041","volume":"38","author":"J Sah","year":"2022","unstructured":"Sah J, Teeple A, Muser E, et al. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases. Curr Med Res Opin. 2022;38(7):1093\u2013101. https:\/\/doi.org\/10.1080\/03007995.2022.2071041.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2942_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/jcpt.12830","volume":"44","author":"S Khan","year":"2019","unstructured":"Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495\u2013507. https:\/\/doi.org\/10.1111\/jcpt.12830.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"2942_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/ibd\/izz001","volume":"25","author":"C Chen","year":"2019","unstructured":"Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417\u201327. https:\/\/doi.org\/10.1093\/ibd\/izz001.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"2942_CR16","doi-asserted-by":"publisher","first-page":"otad051","DOI":"10.1093\/crocol\/otad051","volume":"5","author":"T Goss Sawhney","year":"2023","unstructured":"Goss Sawhney T, Dobes A, O\u2019Charoen S. Real-world persistency for inflammatory bowel disease biologics using patient registry data. Crohns Colitis 360. 2023;5(4):otad051. https:\/\/doi.org\/10.1093\/crocol\/otad051.","journal-title":"Crohns Colitis 360"},{"key":"2942_CR17","unstructured":"Janssen Pharmaceutical Companies. STELARA\u00ae (ustekinumab) Highlights of Prescribing Information 2022. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf. Accessed 24 Jan 2024."},{"issue":"4","key":"2942_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/03007995.2023.2178148","volume":"39","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-na\u00efve patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533\u201343. https:\/\/doi.org\/10.1080\/03007995.2023.2178148.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"2942_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.18553\/jmcp.2023.29.8.907","volume":"29","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29(8):907\u201316. https:\/\/doi.org\/10.18553\/jmcp.2023.29.8.907.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2942_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.18553\/jmcp.2023.29.1.90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90\u2013100. https:\/\/doi.org\/10.18553\/jmcp.2023.29.1.90.","journal-title":"J Manag Care Spec Pharm"},{"key":"2942_CR21","unstructured":"AbbVie Inc. HUMIRA\u00ae (adalimumab) Highlights of Prescribing Information 2021. https:\/\/www.rxabbvie.com\/pdf\/humira.pdf. Accessed 24 Jan 2024."},{"issue":"6","key":"2942_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38(6):1228\u201334. https:\/\/doi.org\/10.1080\/03610910902859574.","journal-title":"Commun Stat Simul Comput"},{"issue":"11","key":"2942_CR23","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s13555-023-01017-8","volume":"13","author":"T Fitzgerald","year":"2023","unstructured":"Fitzgerald T, Zhdanava M, Pilon D, et al. Response to the Letter to the Editor: Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(11):2917\u201323. https:\/\/doi.org\/10.1007\/s13555-023-01017-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"2942_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175099","volume":"12","author":"H Patel","year":"2017","unstructured":"Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn\u2019s disease in the United States. PLoS ONE. 2017;12(4): e0175099. https:\/\/doi.org\/10.1371\/journal.pone.0175099.","journal-title":"PLoS ONE"},{"key":"2942_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/PPA.S238843","volume":"14","author":"K Luttropp","year":"2020","unstructured":"Luttropp K, Dal\u00e9n J, Svedbom A, et al. Real-world patient experience of switching biologic treatment in inflammatory arthritis and ulcerative colitis\u2014a systematic literature review. Patient Preference Adher. 2020;14:309\u201320. https:\/\/doi.org\/10.2147\/PPA.S238843.","journal-title":"Patient Preference Adher."},{"issue":"3","key":"2942_CR26","doi-asserted-by":"publisher","first-page":"otad045","DOI":"10.1093\/crocol\/otad045","volume":"5","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Zhao R, Manceur AM, et al. Persistence and dose escalation during maintenance phase and use of nonbiologic medications among patients with ulcerative colitis initiated on ustekinumab in the United States. Crohns Colitis 360. 2023;5(3):otad045. https:\/\/doi.org\/10.1093\/crocol\/otad045.","journal-title":"Crohns Colitis 360"},{"issue":"10","key":"2942_CR27","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s12325-023-02611-0","volume":"40","author":"B Bressler","year":"2023","unstructured":"Bressler B, Jones J, In TSH, et al. Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023;40(10):4421\u201339. https:\/\/doi.org\/10.1007\/s12325-023-02611-0.","journal-title":"Adv Ther"},{"issue":"11","key":"2942_CR28","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/14712598.2021.1981855","volume":"21","author":"MF Chiappetta","year":"2021","unstructured":"Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483\u20139. https:\/\/doi.org\/10.1080\/14712598.2021.1981855.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2942_CR29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/apt.16544","volume":"54","author":"M Fumery","year":"2021","unstructured":"Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944\u201351. https:\/\/doi.org\/10.1111\/apt.16544.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2942_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/apt.16478","volume":"54","author":"A Blesl","year":"2021","unstructured":"Blesl A, Binder L, H\u00f6genauer C, et al. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther. 2021;54(5):667\u201377. https:\/\/doi.org\/10.1111\/apt.16478.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2942_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ibd\/izy322","volume":"25","author":"L Pouillon","year":"2018","unstructured":"Pouillon L, Baumann C, Rousseau H, et al. Treatment persistence of infliximab versus adalimumab in ulcerative colitis: a 16-year single-center experience. Inflamm Bowel Dis. 2018;25(5):945\u201354. https:\/\/doi.org\/10.1093\/ibd\/izy322.","journal-title":"Inflamm Bowel Dis"},{"key":"2942_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000476","author":"S Hoque","year":"2020","unstructured":"Hoque S, Puenpatom A, Boccaletti S, et al. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol. 2020. https:\/\/doi.org\/10.1136\/bmjgast-2020-000476.","journal-title":"BMJ Open Gastroenterol"},{"issue":"9","key":"2942_CR33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/03007995.2023.2246882","volume":"39","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Ding Z, Manceur AM, et al. Long-term persistence and other treatment patterns among bio-na\u00efve patients with Crohn\u2019s disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(9):1215\u201325. https:\/\/doi.org\/10.1080\/03007995.2023.2246882.","journal-title":"Curr Med Res Opin"},{"key":"2942_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040853","author":"G Privitera","year":"2021","unstructured":"Privitera G, Pugliese D, Rapaccini GL, et al. Predictors and early markers of response to biological therapies in inflammatory bowel diseases. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10040853.","journal-title":"J Clin Med"},{"issue":"2","key":"2942_CR35","first-page":"141","volume":"30","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Zhao R, Manceur AM, et al. Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States. J Manag Care Spec Pharm. 2024;30(2):141\u201352.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2942_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37609","volume":"15","author":"H Awan","year":"2023","unstructured":"Awan H, Fatima U, Eaw R, et al. The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review. Cureus. 2023;15(4): e37609. https:\/\/doi.org\/10.7759\/cureus.37609.","journal-title":"Cureus"},{"issue":"11","key":"2942_CR37","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/apt.18006","volume":"59","author":"TH Yiu","year":"2024","unstructured":"Yiu TH, Ko Y, Pudipeddi A, et al. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(11):1312\u201334. https:\/\/doi.org\/10.1111\/apt.18006.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2942_CR38","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s13555-023-00967-3","volume":"13","author":"AK Das","year":"2023","unstructured":"Das AK, Chang E, Paydar C, et al. Apremilast adherence and persistence in patients with psoriasis and psoriatic arthritis in the telehealth setting versus the in-person setting during the COVID-19 pandemic. Dermatol Ther (Heidelb). 2023;13(9):1973\u201384. https:\/\/doi.org\/10.1007\/s13555-023-00967-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3 suppl","key":"2942_CR39","doi-asserted-by":"publisher","first-page":"AB91","DOI":"10.1016\/j.jaad.2022.06.399","volume":"87","author":"W Gulliver","year":"2022","unstructured":"Gulliver W, Gooderham M, Reed C. Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: results from the Canadian Patient Support Program. J Am Acad Dermatol. 2022;87(3 suppl):AB91.","journal-title":"J Am Acad Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02942-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02942-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:25:25Z","timestamp":1726244725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02942-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02942-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sumesh Kachroo, Sabree Burbage, and Caroline Kerner are employees of Janssen Scientific Affairs, LLC, a Johnson & Johnson Company, and hold stock in the company. Maryia Zhdanava, Porpong Boonmak, Aditi Shah, Jill Korsiak, Patrick Lefebvre, and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, a Johnson & Johnson Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data were de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act of 1996; therefore, no review by an institutional review board was required. Authors had permission to access the data used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}